Skip to main content

Table 1 Eligibility criteria for inclusion into the systematic review

From: Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis

PICO Inclusion criteria Exclusion criteria
Population - Either adults or children
- Diagnosed with STS, including any of the following histologies:
- Liposarcoma
- Leiomyosarcoma
- Undifferentiated pleomorphic sarcoma
- Synovial sarcoma
- Malignant peripheral nerve sheath tumor and triton tumor
- Alveolar soft part sarcoma
- Desmoid tumor
- Solitary fibrous tumor/hemangiopericytoma
- Fibrosarcoma or variants
- Vascular sarcoma
- Epithelioid sarcoma
- Clear cell sarcoma
- Desmoplastic small round cell tumor
- Extraskeletal myxoid chondrosarcoma
- Endometrial stromal sarcoma
- Extraskeletal osteogenic sarcoma
- Other STS not listed in the inclusion list
- Diagnosis of bone sarcoma, including any of the following histologies:
- Osteosarcoma
- Chondrosarcoma
- Ewing’s sarcoma
- Rhabdomyosarcoma
- Articles published up to March 31, 2019
- Articles published that incorporates either a comparison of, or independent listing of populations outlined within intervention and/or comparison group.
- Sarcomatoid epithelial tumors
- Gastrointestinal stromal tumors
Intervention - Studies including subjects who underwent pulmonary, hepatic, or other sites of metastasectomy for recurrent or de novo STS Patients who underwent palliative surgery for symptomatic purposes without complete resection of metastasis (e.g., divert colostomy).
Outcomes - Studies including survival measurement of either a comparison, or individual listing, of intervention and/or comparison group.
- Secondary outcomes include 30-day post-operative mortality, recurrence free survival, time off of systemic therapy, and patient-reported outcomes including quality of life end points where available.
Studies that do not include mortality post metastasectomy as a study outcome